Catalent Inc., which is based in Somerset, said Monday that it would manufacture drug ingredients for AstraZeneca for the COVID-19 ADenovirus vaccine at the University of Oxford, AZD1222.
Catalent will begin production at its advertising gene treatment production plant in Harmans, Maryland, in the third quarter, building its previous pact with AstraZeneca for filling and packaging responsibilities at its Anagni, Italy site.
“Catalent has great delight in the manufacture of viral vectors,” Manja Boerman, president of Catalent Cell – Gene Therapy, said in a list statement. “We are excited to have the features of our flagship Catalent genetic treatment site to expand our program for the AstraZeneca program as we continue to serve our existing genetic treatment clients. Our genetic treatment team is proud to sign up for our colleagues at Catalent Biologics at the Anagni Site to promote AstraZeneca’s COVID-19 candidate vaccine”.
Catalent’s Harmans’ advertising production facility is single-use and houses more than 200,000 square feet of complex production of clinical and advertising gene treatments. The facility is one of five gene therapy facilities in Catalent, Maryland, which supplies clinical facilities on an advertising scale and houses several CGMP production suites, adding filling/finishing, central facilities and test labs, garage and source chain capabilities.
The Catalent Biologics network also includes sterile pharmaceuticals and packaging services in Anagni, Italy; Brussels, Belgium; and Bloomington, Indiana, with more amenities in Europe and the United States for protein production, mobile treatments and biological research services.